Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $21.84 for the day, down -6.27% from the previous closing price of $23.30. In other words, the price has decreased by -$6.27 from its previous closing price. On the day, 0.95 million shares were traded. DNLI stock price reached its highest trading level at $22.86 during the session, while it also had its lowest trading level at $21.69.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.98 and its Current Ratio is at 9.98. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 07, 2025, initiated with a Outperform rating and assigned the stock a target price of $31.
Stifel Upgraded its Hold to Buy on December 16, 2024, while the target price for the stock was maintained at $37.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 3143256576 and an Enterprise Value of 2359257344.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.43, which has changed by 0.4010824 over the last 52 weeks, in comparison to a change of 0.21926713 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is -3.44%, while the 200-Day Moving Average is calculated to be -6.36%.
Shares Statistics:
DNLI traded an average of 953.26K shares per day over the past three months and 877210 shares per day over the past ten days. A total of 143.84M shares are outstanding, with a floating share count of 124.59M. Insiders hold about 13.43% of the company’s shares, while institutions hold 87.77% stake in the company. Shares short for DNLI as of 1736899200 were 7968985 with a Short Ratio of 8.36, compared to 1734048000 on 7464110. Therefore, it implies a Short% of Shares Outstanding of 7968985 and a Short% of Float of 6.4799999999999995.
